跳至主要内容
临床试验/NCT02539329
NCT02539329已完成不适用

Characterization of Sensory Neuropathies Associated With Anti-FGFR3 Antibodies

Centre Hospitalier Universitaire de Saint Etienne17 个研究点 分布在 1 个国家目标入组 251 人开始时间: 2015年2月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
251
试验地点
17
主要终点
Evolution of clinical and electrophysiological pattern of the neuropathy for patients with anti-FGFR3 antibodies (composite measure),

研究概览

简要总结

Sensory neuronopathies affect sensory neuron in the posterior spinal ganglion. They are responsible for pain, balance disorder (ataxia) and the use of hands. They depend on multiple etiologies. In a retrospective study, the investigators showed that the anti-FGFR3 antibody is a diagnostic marker of a subset of sensory neuronopathies. The investigators believe that other antibodies can be discovered in patients who remain seronegative changing.

However, the study is retrospective and only a small number of patients could be identified. Several points therefore need to be clarified or confirmed in a second prospective study.

详细描述

In and out patients evaluated for a sensory neuropathy meeting the inclusion and non-inclusion criteria will be proposed to enter the study

At inclusion the SSN diagnostic score is calculated and a blood sample is tested for anti-FGFR3 antibody.

Follow up: Patients positive for anti-FGFR3 antibodies will be followed and evaluated clinically and electrophysiologically at 1, 6 and 12 months. A blood sample is taken at 6 and 12 months.

A subgroup of patients negative for anti-FGFR3 antibodies will be randomly selected for evaluation at 1, 6 and 12 months.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • A :Patients Male or female patient aged 18 years or more
  • Patients with a clinically pure sensory peripheral neuropathy including :
  • idiopathic or dysimmune sensory neuronopathies
  • idiopathic or dysimmune distal axonal sensory neuropathy
  • sensory chronic inflammatory demyelinating polyradiculoneuropathy
  • idiopathic or dysimmune small fiber neuropathies
  • idiopathic or dysimmune trigeminal nerve neuropathy
  • positive to antibodies anti-FGFR3
  • B :Controls Male or female patient aged 18 years or more
  • Patients with a clinically pure sensory peripheral neuropathy including :
  • idiopathic or dysimmune sensory neuronopathies
  • idiopathic or dysimmune distal axonal sensory neuropathy
  • sensory chronic inflammatory demyelinating polyradiculoneuropathy
  • idiopathic or dysimmune small fiber neuropathies
  • idiopathic or dysimmune trigeminal nerve neuropathy
  • negative to antibodies anti-FGFR3

排除标准

  • -Motor or sensory-motor neuropathies
  • Genetic, toxic, paraneoplasic neuropathies
  • Diabetic Neuropathy.
  • Neuropathy with Anti-MAG or anti-ganglioside IgM.
  • Pregnant or breastfeeding woman

结局指标

主要结局

Evolution of clinical and electrophysiological pattern of the neuropathy for patients with anti-FGFR3 antibodies (composite measure),

时间窗: 6 months

Score to the Overall Disability Scale Score (ODSS), the Rankin Score, the International PrognosticScore (ISS).

次要结局

  • Evolution of clinical and electrophysiological pattern of the neuropathy for patients with anti-FGFR3 antibodies (composite measure),(12 months)
  • Description for patients with anti-FGFR3 antibodies of the immune context(12 months)
  • Patient evolution during one year for patients with anti-FGFR3 antibodies to a control group of sensory neuropathy without antibodies(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (17)

Loading locations...

相似试验